Saturday, March 29, 2025

SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDM™ Platform

Related stories

RoboSense and LionsBot Announce Strategic Partnership

RoboSense, a pioneering AI-driven robotics technology company, and LionsBot,...

Corning Unveils GlassWorks AI Solutions to Support AI Data Center Infrastructure

Corning Incorporated has introduced GlassWorks AI Solutions, a comprehensive...

Workato Acquires DeepConverse to Enhance Generative AI-Powered Automation

Workato, a leader in enterprise automation, has announced the...

Kyndryl Expands Google Cloud Partnership to Drive Mainframe Modernization with Generative AI

Kyndryl, a global IT infrastructure services leader, has announced...
spot_imgspot_img

SOPHiA GENETICS, a cloud-native healthcare technology company and a leader in data-driven medicine, announced that Kepler Uniklinikum, Austria’s second largest hospital, is live on SOPHiA GENETICS’ platform. The hospital will use the SOPHiA DDM Platform to advance its next-generation sequencing (NGS) testing and diagnostics of blood-related cancers.

Kepler Uniklinikum, which has 1,800 beds, is the central healthcare provider for Upper Austria. The hospital will implement the SOPHiA DDM™ Platform across its medical and chemical laboratory locations to deepen its in-house NGS testing capabilities and expand its offerings to its patients, specifically for those faced with blood cancers and disorders.

Also Read: Avicenna.AI secures FDA clearance for AI detection of vertebral compression fractures

Cancer is the second most common cause of death in Austria, with about 42,000 people diagnosed with cancer each year. Additionally, on a global scale, blood cancers are the fifth most common type of cancer in the world. Advances in diagnostics and treatment of blood cancers depend on timely, cost-effective, and reliable sequencing data. The SOPHiA DDM™ Platform uses NGS to target key variants from FFPE, blood, or bone marrow samples, helping lead to fast and accurate detection of variants associated with the disease. The SOPHiA DDM™ Platform is specifically designed to compute a wide array of genomic variants and continually hones its machine learning algorithms to detect genomic variants associated with rare and challenging cases.

“Kepler Uniklinikum’s implementation of the SOPHiA DDM™ Platform will help progress the use of data-driven medicine throughout Austria by ensuring their patients receive the most advanced and accurate testing,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “This testing will not only help the local population but will provide valuable insights and data to support others using the SOPHiA DDM™ Platform around the world.”

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img